LONDON, 4 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX:
HIK) notifies the market that as at 31 March 2008 its capital
consists of 188,301,796 ordinary shares with voting rights. There are
no shares held in treasury.
The above figure (188,301,796) may be used by shareholders as the
denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their
interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and
Transparency Rules.
Ends -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles +44 20 7399 2760
Company Secretary
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics". Hikma's operations are based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader and sells across 17 countries, the United
States and Europe. In 2007, the Group achieved revenues of $449
million (2006 $317 million) and profit attributable to
shareholders of $63 million (2006 $55 million). For news and other
information, please visit www.hikma.com.
---END OF MESSAGE---